Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Saturday's Bonus Content These 3 Stocks Trade at Discounts the Market Won't Ignore ForeverAuthored by Dan Schmidt. First Published: 1/5/2026. 
At a Glance - The S&P 500 posted another gain above 15% in 2025, but the market is now approaching historically concerning valuation levels.
- When valuations are elevated, slowing earnings growth is harshly punished, and investors often turn to value stocks for safety.
- These three large-cap stocks all trade well below their industry-average P/E ratios, which could help protect against market volatility in 2026.
The S&P 500 wrapped up 2025 with a total return of about 18% — the third straight year above historical norms, though below the gangbusters 25% returns of 2023 and 2024. AI euphoria remains the dominant market theme entering 2026, and the usual suspects like NVIDIA Corp. (NASDAQ: NVDA) and Alphabet Inc. (NASDAQ: GOOGL) were higher again on the first trading day. If you've ridden the AI rally since the market bottomed in 2022, you're likely sitting on substantial gains and may feel compelled to diversify, especially if your allocation is tech-heavy. The S&P 500 is entering the year trading at roughly 26x forward earnings, well above its 20-year average of about 16x. When valuations are this elevated, investors become ravenous for earnings growth, and high-multiple stocks can fall out of favor quickly if growth cools even slightly. If interest rates remain high, 2026 could be the year value investing stages a comeback. Ray Dalio Says "Gold Is the Future". This ETF Pays You 64% to Own It
Ray Dalio is urging investors to shift 10% of their portfolio into gold. But one ETF lets you go a step further: earn up to $1,152/month.
It's part of a new wave of funds that pay you every 30 days. Watch the video now and discover the #1 fund for monthly payouts. Below are three ways to de-risk a portfolio by buying stocks that enter the new year undervalued and overlooked. Each company trades at a sizable valuation discount to its industry peers, yet both fundamental and technical tailwinds suggest those discounts may not last. Comcast: Strong Balance Sheet and Sports Expansion Enhance Outlook The Comcast Corp. (NASDAQ: CMCSA) was one of the biggest victims of the cord-cutting revolution, as customers fled expensive cable packages for a la carte streaming services. CMCSA is nearly a decade into a slump, trading at about the same price it did in May 2016. Now customers are showing signs of cord-cutting fatigue as streamers raise prices and enter costly disputes with major networks. Meanwhile, Comcast has quietly built a sturdy balance sheet and diversified revenue streams. Its forward price-to-earnings (P/E) ratio of 6.84 is well below the communications industry average (16.5) and far lower than major competitors like The Walt Disney Co. (NYSE: DIS) and AT&T Inc. (NYSE: T). 
Comcast's broadband business remains a steady, high-margin cash flow engine. Despite Connectivity and Platforms revenue slowing 1.4% year-over-year (YOY) in Q3 2025, EBITDA margins for the residential and business segments were 37% and 56%, respectively. The advertising business also stands to benefit in 2026: NBCUniversal holds U.S. rights to Super Bowl LX, the FIFA World Cup, and the Winter Olympics in Italy. The company generated $4.9 billion in free cash flow in Q3 2025, helping to support its 4.4% dividend. Comcast's value story may not remain a secret much longer — the stock is up nearly 10% over the last 30 days, and several technical indicators point to further upside. Micron: An Essential AI Stock Trading at a Deep Discount How can a stock that just delivered roughly a 200% year still trade at a discount? Despite its meteoric 2025, Micron Technology Inc. (NASDAQ: MU) remains comparatively cheap within the AI and semiconductor complex, trading around 29x earnings while the broader tech sector sits near 75x. A P/E of 29 isn't a bargain versus the overall market, but it looks attractive given Micron's growth profile. The company is producing roughly 57% year-over-year quarterly revenue growth, generating 57% gross margins, and repeatedly raising guidance each quarter. 
Memory businesses tend to be high-margin, and Micron management says it is struggling to keep up with insatiable demand from data centers. The chart shows a healthy uptrend with support along the 50-day simple moving average (SMA). That aligns with the TradeSmith Health indicator, a tool that gauges trend viability — in this case, MU shares are in the Green Zone, indicating a robust uptrend with orderly pullbacks. Pfizer: Fueling Pipeline Innovation Through Acquisitions Shares of healthcare giant Pfizer Inc. (NYSE: PFE) have struggled since the COVID-19 pandemic receded; the stock is down more than 30% over the last five years. Rivals like Eli Lilly and Co. (NYSE: LLY) have leapfrogged Pfizer thanks to obesity treatments such as Mounjaro, but Pfizer now trades near historical lows in valuation (about 8.4x forward earnings) and is cheaper than most large-cap pharmaceutical peers. The company's Seagen acquisition is beginning to pay off in oncology, adding more than $6 billion in revenue since the deal closed in 2023. 
Although Pfizer's pivot into the obesity drug market has been slower than some investors expected, it has bolstered its pipeline by acquiring two smaller drugmakers that offer oral and injectable treatment options. The market has largely written Pfizer off in this space, which helps explain the valuation gap. Low expectations often create opportunities — the stock doesn't fully reflect the possibility that Pfizer could make meaningful inroads into the GLP-1 market. Plus, Pfizer can serve as a defensive holding given its low valuation and a record of dividend growth.
| 
